ZR2 Bioenergy

Why is ZR2 Bioenergy Ltd falling/rising?

As of 01-Sep, ZR2 Bioenergy Ltd's stock price is currently at 109.15, reflecting a decline of 4.96% and significant volatility. The stock has underperformed its sector and has dropped 62.36% year-to-date, indicating a bearish trend despite increased investor participation.

As of 01-Sep, ZR2 Bioenergy Ltd's stock price is falling, currently at 109.15, which reflects a decrease of 5.7 or 4.96%. The stock has underperformed its sector by 4.54% today. It reached an intraday high of Rs 120.55 but also touched a low of Rs 109.15, indicating significant volatility within the trading day. <BR><BR>Over the past week, the stock has declined by 7.71%, while the benchmark Sensex has only decreased by 0.92%. Year-to-date, ZR2 Bioenergy has seen a substantial drop of 62.36%, compared to a 9.71% decline in the Sensex. Additionally, the stock has been trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. <BR><BR>Despite a rise in investor participation, with delivery volume increasing by 86.07% against the 5-day average, the overall performance indicates a lack of positive momentum. The stock's wide trading range of Rs 11.4 further emphasizes the instability in its price movements. Overall, these factors contribute to the current decline in ZR2 Bioenergy Ltd's stock price.

Which are the latest news on ZR2 Bioenergy?

Who are in the management team of ZR2 Bioenergy?

The management team of ZR2 Bioenergy includes Sagar Shah (Chairman), Sangeeta Khyani (Company Secretary), Barkha Balkrushnan Deshmukh (Independent Director), Viraj Samirbhai Shah (Whole-time Director), Sunil Kondiba Kalhapure (Independent Director), and Rajasvee Shah (Non-Executive Director).

The management team of ZR2 Bioenergy includes the following individuals:<BR><BR>1. **Sagar Shah** - Chairman (Non-Executive)<BR>2. **Sangeeta Khyani** - Company Secretary & Compliance Officer<BR>3. **Barkha Balkrushnan Deshmukh** - Independent Director<BR>4. **Viraj Samirbhai Shah** - Whole-time Director<BR>5. **Sunil Kondiba Kalhapure** - Independent Director<BR>6. **Rajasvee Shah** - Non-Executive Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does ZR2 Bioenergy do?

ZR2 Bioenergy Ltd is a micro-cap company in the commodity chemicals industry, with a market cap of INR 183 Cr and recent quarterly results showing a net profit of 0 Cr. Established in 1911, it has undergone several name and status changes, currently operating under the name Gujchem Distillers India Limited.

Overview:<BR>ZR2 Bioenergy Ltd operates in the commodity chemicals industry and is categorized as a micro-cap company.<BR><BR>History:<BR>ZR2 Bioenergy Limited was initially established in 1911 and underwent several status changes, becoming a Private Limited Company in 1939, a Public Limited Company in 1961, and changing its name to Gujchem Distillers India Limited in 1974. The most recent quarterly results reported are for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>Market-cap value: INR 183 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 199.00<BR>Industry P/E: 43<BR>Dividend Yield: 0.02%<BR>Debt Equity: -0.13<BR>Return on Equity: 0.72%<BR>Price to Book: 1.25<BR><BR>Contact Details:<BR>Address: No 6 2nd Flr National Chambers, Nr City Gold Ashram Road Ahmedabad Gujarat : 380009<BR>Tel: 91-7926580893<BR>Email: gujcheminvestors@gmail.com<BR>Website: http://www.gujchemdistillers.com

Who are the peers of the ZR2 Bioenergy?

ZR2 Bioenergy's peers include Genus Prime, Hind.Organ.Chem., IVP, ARCL Organics, Kanchi Karpooram, Kesar Petroprod., Archit Organosys, Sh. Hari Chem., and AG Ventures, with ZR2 showing below-average management risk and a 1-year return of -70.89%. Sh. Hari Chem. leads in returns at 101.43%, while Kesar Petroprod. has the lowest at -58.28%.

Peers: The peers of ZR2 Bioenergy are Genus Prime, Hind.Organ.Chem., IVP, ARCL Organics, Kanchi Karpooram, Kesar Petroprod., Archit Organosys, Sh. Hari Chem., and AG Ventures.<BR><BR>Quality Snapshot: Excellent management risk is observed at ARCL Organics and Kanchi Karpooram, while Average management risk is found at IVP and Sh. Hari Chem. Below Average management risk is present at Genus Prime, Hind.Organ.Chem., ZR2 Bioenergy, Kesar Petroprod., Archit Organosys, and AG Ventures. Good growth is noted at Genus Prime, ARCL Organics, Kesar Petroprod., and Sh. Hari Chem., while Below Average growth is seen at Hind.Organ.Chem., IVP, ZR2 Bioenergy, Kanchi Karpooram, and the rest. Excellent capital structure is held by Kanchi Karpooram and AG Ventures, while Good capital structure is noted at ARCL Organics, and Below Average capital structure is observed at Genus Prime, Hind.Organ.Chem., IVP, ZR2 Bioenergy, Kesar Petroprod., Archit Organosys, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sh. Hari Chem. at 101.43%, while Kesar Petroprod. has the lowest at -58.28%. ZR2 Bioenergy's 1-year return is -70.89%, which is lower than both of these peers. Additionally, Kesar Petroprod. and ZR2 Bioenergy have negative six-month returns.

How big is ZR2 Bioenergy?

As of 31st August, ZR2 Bioenergy Ltd has a market capitalization of 183.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit of 0.92 Cr in the latest four quarters. Shareholder's Funds are 139.34 Cr and Total Assets are 139.50 Cr as of March 2025.

As of 31st August, ZR2 Bioenergy Ltd has a market capitalization of 183.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, ZR2 Bioenergy reported Net Sales of 0.00 Cr and a Net Profit of 0.92 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 139.34 Cr and Total Assets of 139.50 Cr.

When is the next results date for ZR2 Bioenergy Ltd?

The next results date for ZR2 Bioenergy Ltd is 29 May 2026.

The next results date for ZR2 Bioenergy Ltd is scheduled for 29 May 2026.

How has been the historical performance of ZR2 Bioenergy?

ZR2 Bioenergy's historical performance from March 2022 to March 2025 shows increased net sales and operating income, but a decline in profitability and operational efficiency, with profit after tax dropping significantly and operating profit margin turning negative. Despite stable liabilities and positive cash flow from operations, the company faced challenges in maintaining profitability.

Answer:<BR>The historical performance of ZR2 Bioenergy shows a mixed trend in financial metrics from March 2022 to March 2025.<BR><BR>Breakdown:<BR>ZR2 Bioenergy's net sales increased from 1.16 Cr in March 2022 to 1.49 Cr in March 2025, while total operating income also rose to 1.49 Cr from 1.16 Cr during the same period. However, the company's total expenditure saw a significant rise from 1.11 Cr to 1.90 Cr, leading to an operating profit (PBDIT) decline from 0.32 Cr to 0.23 Cr. The operating profit margin (excluding other income) fell sharply from 4.31% to -27.52%, indicating a deterioration in operational efficiency. Profit before tax decreased from 0.32 Cr to 0.20 Cr, and profit after tax dropped significantly from 0.39 Cr to 0.09 Cr, resulting in a PAT margin decline from 33.62% to 6.04%. On the balance sheet, total liabilities remained stable at 139.50 Cr, with shareholder's funds at 139.34 Cr. The cash flow from operating activities was positive at 31.00 Cr, while cash flow from investing activities was negative at -116.00 Cr, and financing activities contributed 100.00 Cr, leading to a net cash inflow of 14.00 Cr and a closing cash balance of 19.00 Cr. Overall, while sales and income showed growth, profitability and operational efficiency faced challenges.

Should I buy, sell or hold ZR2 Bioenergy?

Are ZR2 Bioenergy latest results good or bad?

ZR2 Bioenergy's latest results show improved profitability with a Profit After Tax increase, but net sales remain flat and operational challenges persist, leading to a 'Sell' rating from analysts. Overall, the results are mixed, indicating both positive and negative aspects.

ZR2 Bioenergy's latest results present a mixed picture. On one hand, the company has shown a significant improvement in profitability, with Profit After Tax (PAT) rising to Rs 0.42 crore for the latest six-month period, a substantial increase from Rs 0.06 crore in the previous year. This indicates that the company is on a positive trajectory in terms of profitability.<BR><BR>However, the overall financial performance remains flat, with net sales showing no growth compared to the previous year. Additionally, the Debtors Turnover Ratio has declined to 0.00 times, suggesting challenges in the company's ability to manage its debts effectively. This raises concerns about operational efficiency.<BR><BR>Furthermore, the stock is currently rated as a 'Sell' by MarketsMOJO, which reflects a cautious outlook from market analysts. Overall, while there are positive signs in profitability, the lack of growth in sales and operational challenges indicate that the results are not entirely favorable.

Who are the top shareholders of the ZRZ Bioenergy?

The top shareholders of ZRZ Bioenergy are Zr2 Group Holdings Ltd with 60.96% of shares, followed by public shareholder Manish Ruparel at 9.92%. Individual investors collectively own 37.43%, with no mutual funds or foreign institutional investors involved.

The top shareholders of ZRZ Bioenergy include Zr2 Group Holdings Ltd, which holds a significant 60.96% of the shares. Additionally, the highest public shareholder is Manish Ruparel, who owns 9.92%. Individual investors collectively hold 37.43% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) involved in the company's shareholding.

Is ZRZ Bioenergy overvalued or undervalued?

As of February 14, 2025, ZRZ Bioenergy is considered risky and overvalued with a PE ratio of -146.27 and significant financial distress, contrasting sharply with peers like Godrej Industries and Deepak Nitrite, despite having outperformed the Sensex over the past year.

As of 14 February 2025, the valuation grade for ZRZ Bioenergy has moved from very expensive to risky. The company is currently assessed as overvalued. Key ratios reveal a PE ratio of -146.27, an EV to EBITDA of -127.26, and a Price to Book Value of 1.05, indicating significant financial distress and a lack of profitability.<BR><BR>In comparison to its peers, ZRZ Bioenergy's valuation metrics starkly contrast with companies like Godrej Industries, which has a PE ratio of 46.63 and an EV to EBITDA of 34.36, and Deepak Nitrite, with a PE of 37.97 and an EV to EBITDA of 24.57. The substantial differences in these ratios highlight the challenges ZRZ Bioenergy faces within the commodity chemicals sector. Additionally, while ZRZ Bioenergy has outperformed the Sensex over the past year with a return of 87.11% compared to the Sensex's 7.65%, the underlying valuation suggests that this performance may not be sustainable given its current financial metrics.

What is the technical trend for ZRZ Bioenergy?

As of May 28, 2025, ZRZ Bioenergy shows a mildly bullish trend supported by the weekly MACD and Bollinger Bands, despite mixed signals from daily moving averages and the monthly MACD.

As of 28 May 2025, the technical trend for ZRZ Bioenergy has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bearish, indicating some caution. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the upward momentum. However, daily moving averages are mildly bearish, suggesting short-term weakness. The KST is mildly bullish on the weekly and mildly bearish on the monthly, adding to the mixed signals. Dow Theory indicates a mildly bullish stance on both weekly and monthly charts. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands.

Has ZRZ Bioenergy declared dividend?

No Dividend History Available